Physician profile
Tami Orton
NPI 1407452873
$7,637.75
in general payments reported to CMS, 2019-2025
25 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $328 · 2023: $1,171 · 2024: $3,051 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709 · Travel and Lodging: $899 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.91 |
| Travel and Lodging | $898.82 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,693.58 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,534.64 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $976.80 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $467.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $408.17 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $392.68 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $310.28 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $303.91 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $259.35 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $221.64 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $215.75 | 2021-2025 | Aristada, Lybalvi |
| Harmony Biosciences LLC | $173.42 | 2023-2025 | Wakix |
| Vanda Pharmaceuticals INC. | $95.20 | 2022-2024 | Fanapt |
| Tris Pharma INC | $89.97 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $88.20 | 2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $76.25 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $64.06 | 2023 | Quviviq |
| Neos Therapeutics, LP | $55.03 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $53.22 | 2021-2025 | Trintellix |
| Corium, LLC | $48.20 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $35.90 | 2021 | |
| Biogen, INC. | $29.50 | 2025 | Zurzuvae |
| Indivior INC. | $17.47 | 2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $14.16 | 2024 | |
| Avanir Pharmaceuticals, INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Orton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.